Key Highlights
● Third-quarter Revenue was $72.0 million, down 19.4% from a year earlier.
● The net loss was $17.5 million, versus an adjusted net loss of $2.1 million.
● Active earning coaches fell 47.7% to 10,200.
● The company ended the quarter with $172.5 million in cash and investments and no debt.
Medifast, Inc. (NYSE:MED), the company behind the OPTAVIA coach-led health and weight-management model, is in the middle of a cost overhaul it calls the Catalyst program. Its third-quarter report on Oct. 26, 2026 showed a large GAAP loss driven by restructuring charges, yet adjusted margins moved higher. For investors trying to separate one-time costs from underlying profitability, the gap between those two pictures may be one of the more important features of the company's current financial profile. That divergence comes as the company also reshapes its coach network.
Latest Company Context
Medifast reported third-quarter revenue of $72.0 million, down 19.4% from a year earlier, and a net loss of $17.5 million, or $1.57 per diluted share, compared with a $2.3 million loss a year earlier, according to its release. Excluding Catalyst restructuring charges, the adjusted net loss was $2.1 million, or $0.19 per share. Active earning coaches fell 47.7% to 10,200, while revenue per active earning coach rose 54.1% to $7,064.
The company ended the quarter with $172.5 million in cash, cash equivalents and Investment securities and no debt. It guided fourth-quarter revenue to $55 million to $75 million and EPS of $0.00 to $0.25. Full-year guidance calls for revenue of $280 million to $300 million and a GAAP loss of $1.80 to $2.05 per share, or a non-GAAP loss of $0.45 to $0.70. Nick Johnson became chief executive on June 1, 2026.
Key Business and index Drivers
The Margin detail is where Catalyst shows up. GAAP gross margin was flat at 69.5%, as restructuring charges of roughly 230 basis points offset the absence of prior-year reformulation costs; adjusted gross margin rose 220 basis points to 71.7%. GAAP SG&A increased 4.8% to $69.4 million, or 96.3% of revenue, because of a $13.8 million Catalyst charge, but adjusted SG&A fell 16.0% to $55.6 million. The program, launched in the second quarter, aims to shrink and reassess the distribution network, streamline internal software and align resources with revenue.
CEO Nick Johnson said the company is on track to deliver profitability in the fourth quarter. Coach compensation also declined with lower volume, which mechanically reduces costs as revenue falls. Adjusted SG&A still equaled 77.2% of revenue, which shows how much of the cost base remains relative to a smaller top line. The fourth-quarter EPS guidance range of zero to $0.25 implies management expects costs to fall further.
What Investors Should Watch
The fourth-quarter report, expected in early 2027, will test whether the company reaches the profitability implied by its guidance and whether restructuring charges taper. Investors may watch adjusted SG&A as a share of revenue, since cost cuts need to keep pace with a shrinking top line. Full-year guidance calls for adjusted EBITDA excluding interest income of $10 million to $14 million. Management expects coach counts to keep declining through year-end, so any stabilization would be notable. Uptake of Trilivy, the new coach compensation plan and the Coach Hub, now launched, could influence whether productivity gains continue. The company has not quantified total expected Catalyst savings, so any future disclosure could help. Updates from the Medifast Metabolic Health Institute, launched in August, may also support the company's clinical positioning.
Reported Losses Versus Adjusted Margin Gains
Medifast's third quarter illustrates how restructuring can depress reported results while adjusted margins improve. Whether Catalyst creates a leaner, sustainably profitable business depends on revenue eventually stabilizing alongside lower costs. The company's debt-free Balance Sheet gives it room to execute, and the fourth quarter may offer the first clean read on whether the program's savings translate into positive earnings. The wide fourth-quarter revenue range of $55 million to $75 million also signals considerable uncertainty, so investors may treat cost discipline as one of the more controllable variables in the outlook.






Please wait processing your request...